DK1071752T3 - CD19xCD3-specifikke polypeptider og anvendelsen deraf - Google Patents

CD19xCD3-specifikke polypeptider og anvendelsen deraf

Info

Publication number
DK1071752T3
DK1071752T3 DK99924816T DK99924816T DK1071752T3 DK 1071752 T3 DK1071752 T3 DK 1071752T3 DK 99924816 T DK99924816 T DK 99924816T DK 99924816 T DK99924816 T DK 99924816T DK 1071752 T3 DK1071752 T3 DK 1071752T3
Authority
DK
Denmark
Prior art keywords
polypeptides
polynucleotides
vectors
compositions
afore
Prior art date
Application number
DK99924816T
Other languages
English (en)
Inventor
Ralf Lutterbuese
Ralf Bargou
Gert Riethmueller
Anja Loeffler
Peter Kufer
Bernd Doerken
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1071752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micromet Ag filed Critical Micromet Ag
Application granted granted Critical
Publication of DK1071752T3 publication Critical patent/DK1071752T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK99924816T 1998-04-21 1999-04-21 CD19xCD3-specifikke polypeptider og anvendelsen deraf DK1071752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107269 1998-04-21
PCT/EP1999/002693 WO1999054440A1 (en) 1998-04-21 1999-04-21 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK1071752T3 true DK1071752T3 (da) 2003-10-20

Family

ID=8231795

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924816T DK1071752T3 (da) 1998-04-21 1999-04-21 CD19xCD3-specifikke polypeptider og anvendelsen deraf

Country Status (29)

Country Link
US (2) US7112324B1 (da)
EP (2) EP1071752B1 (da)
JP (1) JP4169478B2 (da)
KR (1) KR100508289B1 (da)
CN (1) CN1302103C (da)
AT (1) ATE244758T1 (da)
AU (1) AU761587B2 (da)
BR (1) BRPI9909860B8 (da)
CA (1) CA2326389C (da)
CU (1) CU23252B7 (da)
CZ (1) CZ302070B6 (da)
DE (1) DE69909459T2 (da)
DK (1) DK1071752T3 (da)
ES (1) ES2203141T3 (da)
HK (1) HK1037674A1 (da)
HR (1) HRP20000714B1 (da)
HU (1) HU229039B1 (da)
ID (1) ID27512A (da)
IL (2) IL138857A0 (da)
NO (1) NO326523B1 (da)
NZ (1) NZ507381A (da)
PL (1) PL199747B1 (da)
PT (1) PT1071752E (da)
RU (1) RU2228202C2 (da)
SI (1) SI1071752T1 (da)
SK (1) SK286683B6 (da)
TR (1) TR200003087T2 (da)
WO (1) WO1999054440A1 (da)
ZA (1) ZA200005866B (da)

Families Citing this family (416)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100508289B1 (ko) * 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
EP1543839B1 (en) * 1999-06-09 2017-09-20 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
AU782160B2 (en) * 1999-06-09 2005-07-07 Immunomedics Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
RU2005141512A (ru) * 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
DE602004025101D1 (de) 2003-05-31 2010-03-04 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
ES2358427T3 (es) 2003-10-16 2011-05-10 Micromet Ag Elementos de unión a cd-3 desinmunizados multiespecíficos.
ATE459374T1 (de) * 2003-11-28 2010-03-15 Micromet Ag Polypeptide enthaltende zusammensetzungen
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
DE602005022830D1 (de) * 2004-02-16 2010-09-23 Micromet Ag Weniger immunogene bindungsmoleküle
EP1774017B1 (en) 2004-07-26 2013-05-15 Pfenex Inc. Process for improved protein expression by strain engineering
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
CA2597924C (en) * 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
RS54127B1 (en) 2005-04-18 2015-12-31 Amgen Research (Munich) Gmbh ANTIBODIES NEUTRALIZERS OF THE HUMAN FACTOR OF STIMULATION OF THE COLONIA OF THE GRANULLocyte MACROPHAGUS
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
JP5442998B2 (ja) * 2005-12-16 2014-03-19 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 腫瘍性疾患を処置するための手段および方法
BRPI0620632A2 (pt) 2005-12-21 2011-12-20 Micromet Ag composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits
US20090221024A1 (en) * 2006-03-02 2009-09-03 Antitope Limited T cell assays
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR101940944B1 (ko) † 2007-04-03 2019-01-22 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
KR101626988B1 (ko) * 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
HUE040467T2 (hu) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2069401A4 (en) * 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US9096832B2 (en) * 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
SI2211904T1 (sl) * 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
WO2010037837A2 (en) 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
JP5647132B2 (ja) 2008-11-07 2014-12-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 急性リンパ芽球性白血病の治療
DK3330293T3 (da) 2008-11-07 2019-10-07 Amgen Res Munich Gmbh Behandling af pædiatrisk akut lymfoblastær leukæmi med bispecifikke antistoffer mod CD3xCD19
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP2012531418A (ja) 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体タンパク質に結合する二重特異性抗体
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
PL2493503T5 (pl) 2009-10-27 2021-05-31 Amgen Research (Munich) Gmbh Schemat dawkowania do podawania dwuswoistego przeciwciała CD19xCD3
WO2011069104A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
PT2560947T (pt) 2010-04-19 2016-11-24 Oryzon Genomics Sa Inibidores da desmetilase específica de lisina 1 e seu uso
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
JP5636091B2 (ja) 2010-05-05 2014-12-03 ウニベルジテート バイロイト 癌治療に用いるためのコンブレタスタチン類似体
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
US20130123367A1 (en) 2010-07-28 2013-05-16 Medizinische Universitat Wien Vinylogous chalcone derivatives and their medical use
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
DK2598482T3 (da) 2010-07-29 2018-06-14 Oryzon Genomics Sa Arylcyclopropylamin-basererede demethylaseinhibitorer af lsd1 og deres medicinske anvendelse
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
ME02311B (me) 2010-10-27 2016-06-20 Amgen Res Munich Gmbh Sredstva za liječenje i postupci liječenja dlbcl
EP3831386A1 (en) * 2010-11-10 2021-06-09 Amgen Research (Munich) GmbH Prevention of adverse effects caused by cd3 specific binding domains
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CN103648529A (zh) 2011-04-28 2014-03-19 安进研发（慕尼黑）股份有限公司 用于给处于潜在不良反应的风险的患者施用CD19xCD3双特异性抗体的给药方案
NZ703939A (en) 2011-05-21 2016-01-29 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
RU2708977C2 (ru) 2011-06-10 2019-12-12 МЕДИММЬЮН, ЭлЭлСи Молекулы, связывающиеся с psl pseudomonas, и пути их применения
SG10201606785UA (en) * 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
DE102012016127A1 (de) 2011-08-31 2013-02-28 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2849564C (en) 2011-10-20 2020-10-20 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
PL2776065T3 (pl) 2011-11-07 2020-12-14 Medimmune Limited Terapie skojarzone z zastosowaniem cząsteczek wiążących przeciwko psl i pcrv pseudomonas
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2817318A4 (en) 2012-02-22 2016-04-27 Univ Pennsylvania COMPOSITIONS AND METHOD FOR GENERATING A PERSISTENT POPULATION OF T CELLS FOR CANCER TREATMENT
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2864177C (en) 2012-03-01 2019-11-26 Amgen Research (Munich) Gmbh Prolonged half-life albumin-binding protein fused bispecific antibodies
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
HRP20220399T1 (hr) 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN103965359B (zh) * 2013-01-24 2016-08-03 上海市肿瘤研究所 抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
CA2903096A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
JP6420776B2 (ja) 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014140358A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
JP6480907B2 (ja) * 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 多量体化技術
US9561291B2 (en) * 2013-03-15 2017-02-07 Imre Kovesdi Methods of targeting T-cells to tumors
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP3415534A1 (en) 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
AU2014287244B2 (en) * 2013-07-09 2017-06-15 Duke University Certain improved human bispecific EGFRvIII antibody engaging molecules
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
RU2577226C2 (ru) * 2014-04-10 2016-03-10 Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
RU2568910C2 (ru) * 2014-04-18 2015-11-20 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний
CN105017422A (zh) * 2014-04-30 2015-11-04 山东百因制药技术有限公司 一种抗cd3/抗cd19双特异性抗体及其应用
CA2946230A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
WO2015172341A1 (zh) * 2014-05-14 2015-11-19 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
CA2948771C (en) 2014-05-30 2023-10-17 Amgen Research (Munich) Gmbh Risk-stratification of b-precursor acute lymphoblastic leukemia patients
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP3172235A2 (en) 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AR101936A1 (es) 2014-07-31 2017-01-25 Amgen Res (Munich) Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
US10280156B2 (en) 2014-08-28 2019-05-07 Medizinische Universität Wien Heteroaromatic chalcone derivatives and their medical use
WO2016077789A1 (en) 2014-11-14 2016-05-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
MX2017006312A (es) 2014-11-17 2017-08-21 Regeneron Pharma Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
AU2016210068B2 (en) 2015-01-23 2021-10-28 Sanofi Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
JP6959869B2 (ja) 2015-02-23 2021-11-05 シーガル セラピューティクス エスアーエス 非天然セマフォリン３およびそれらの医学的使用
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
CN107580603A (zh) 2015-02-24 2018-01-12 生物蛋白有限公司 条件活性生物蛋白
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
US10562960B2 (en) 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
WO2016164558A1 (en) * 2015-04-07 2016-10-13 Children's Medical Center Corporation Methods and compositions relating to an embryonic stem cell-based tumor model
MA43197A (fr) 2015-04-17 2018-09-19 Amgen Res Munich Gmbh Constructions d'anticorps bispécifiques pour cdh3 et cd3
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
WO2016170102A1 (en) 2015-04-22 2016-10-27 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
WO2016180982A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
EP3294768B1 (en) 2015-05-13 2019-08-21 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
AU2016271113B2 (en) 2015-05-29 2022-09-08 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN106349391A (zh) * 2015-07-17 2017-01-25 中国科学院深圳先进技术研究院 Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
MX2018002226A (es) 2015-08-28 2018-03-23 Amunix Operating Inc Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
EP3328885A1 (en) 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
RU2022108079A (ru) 2015-09-24 2022-04-08 Дайити Санкио Компани, Лимитед Антитело против garp
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
EP3371349A4 (en) 2015-11-02 2018-09-12 Bioatla, LLC Conditionally active polypeptides
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
CN105296421B (zh) * 2015-11-24 2019-01-29 高岱清 一种双特异性抗体活化的t细胞及制备方法与应用
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
HUE056897T2 (hu) 2015-12-09 2022-03-28 Univ Wien Med Monomaleimid-funkcionalizált platinavegyületek rákterápiához
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201806150RA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
BR112018015715A2 (pt) 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
AU2017220611A1 (en) 2016-02-15 2018-08-30 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh TAF1 inhibitors for the therapy of cancer
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3018382A1 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
WO2017178572A1 (en) * 2016-04-13 2017-10-19 Vivia Biotech, S.L Ex vivo bite-activated t cells
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CN109310385A (zh) 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CN105906720A (zh) * 2016-05-16 2016-08-31 武汉汉密顿生物科技股份有限公司 靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
US10669338B2 (en) 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CA3029426A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US11584780B2 (en) 2016-07-26 2023-02-21 Biomarin Pharmaceutical Inc. Adeno-associated virus capsid proteins
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
US20190307799A1 (en) 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
JP7096240B2 (ja) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合ｃ５の定量化方法
JP2020511401A (ja) 2016-11-14 2020-04-16 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのｂｒｄ４阻害剤と葉酸代謝拮抗薬との組み合わせ物
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
JP2020503015A (ja) * 2016-12-13 2020-01-30 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
CN108264566B (zh) * 2016-12-30 2021-05-14 惠和生物技术(上海)有限公司 一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN108659112B (zh) * 2017-03-30 2021-01-26 上海市同济医院 一种非对称双特异性抗体
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11447564B2 (en) 2017-04-26 2022-09-20 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3645048A4 (en) * 2017-06-25 2021-06-16 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
MA56289B1 (fr) 2017-08-03 2022-04-29 Amgen Inc Mutéines d'interleukine-21 et méthodes de traitement
PE20212205A1 (es) 2017-09-08 2021-11-18 Maverick Therapeutics Inc Proteinas de union condicionalmente activadas restringidas
EP4141005B1 (en) 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
BR112020004902A2 (pt) 2017-09-15 2020-09-15 Amgen Inc. processo para formulação farmacêutica liofilizada de uma proteína terapêutica
CA3078974A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
MX2020003395A (es) 2017-10-13 2020-08-03 Merck Sharp & Dohme Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
WO2019075405A1 (en) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
EP3704153A2 (en) 2017-11-02 2020-09-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
BR112020011627A2 (pt) 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN107987169B (zh) * 2018-01-05 2021-10-08 阿思科力(苏州)生物科技有限公司 一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
RU2020130795A (ru) 2018-02-21 2022-03-21 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Нейтрализующие антитела к env вич-1 и их применение
CN112119099A (zh) 2018-03-02 2020-12-22 Cdr-生物科技股份有限公司 三特异性抗原结合蛋白
JP7154634B2 (ja) * 2018-03-13 2022-10-18 国立大学法人大阪大学 腫瘍免疫賦活剤
EP3768281B1 (en) 2018-03-19 2023-07-05 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112384533A (zh) 2018-04-18 2021-02-19 埃克塞里艾克西斯公司 抗-ror抗体构建体
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US11739345B2 (en) 2018-05-09 2023-08-29 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210230242A1 (en) 2018-06-18 2021-07-29 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
MA53094A (fr) 2018-07-02 2021-05-12 Amgen Inc Protéine de liaison à l'antigène anti-steap1
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
CA3105729A1 (en) 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
PE20211400A1 (es) 2018-08-03 2021-07-27 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3
MX2021002190A (es) 2018-08-31 2021-05-14 Regeneron Pharma Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
US11066476B2 (en) 2018-09-14 2021-07-20 Shanghai tongji hospital Asymmetric bispecific antibody
CN110590955B (zh) * 2018-09-17 2021-05-18 北京盛诺基医药科技股份有限公司 一种双特异性抗体
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
TW202028239A (zh) 2018-09-28 2020-08-01 美商安進公司 針對可溶性bcma之抗體
KR20210069641A (ko) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
MX2021004510A (es) 2018-10-23 2021-06-08 Amgen Inc Calibracion automatica y mantenimiento automatico de modelos espectroscopicos de raman para predicciones en tiempo real.
SG11202104900SA (en) 2018-11-20 2021-06-29 Univ Cornell Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2020132214A2 (en) 2018-12-20 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
TW202043253A (zh) 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
US20220137010A1 (en) 2019-02-20 2022-05-05 Amgen Inc. Methods of determining protein stability
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
US11685780B2 (en) 2019-03-05 2023-06-27 Takeda Pharmaceutical Company Limited Single domain antigen binding domains that bind human Trop2
WO2020198538A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
EP3962948A1 (en) 2019-04-30 2022-03-09 Amgen Research (Munich) GmbH Means and methods of treating burkitt lymphoma or leukemia
US20220227853A1 (en) 2019-05-03 2022-07-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
CN114269783B (zh) 2019-07-02 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 结合egfrviii的单克隆抗体及其应用
CN110623921B (zh) * 2019-08-15 2020-10-30 北京东方百泰生物科技股份有限公司 一种抗cd3和抗cd19的双特异性抗体注射制剂
RU2738802C1 (ru) 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
MX2022003933A (es) 2019-10-02 2022-04-25 Domain Therapeutics Antagonistas del receptor ep4 de prostaglandina e2 (pge2).
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP3808741A1 (en) 2019-10-16 2021-04-21 CeMM - Forschungszentrum für Molekulare Medizin GmbH Compounds for targeted degradation of carrier proteins and uses thereof
EP4045142A1 (en) 2019-10-16 2022-08-24 CeMM - Forschungszentrum für Molekulare Medizin GmbH Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP4054590A1 (en) 2019-11-04 2022-09-14 Amgen Inc. Methods for treating leukemia
EP3819312A1 (en) 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
LT3819007T (lt) 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021154839A1 (en) 2020-01-30 2021-08-05 Umoja Biopharma, Inc. Bispecific transduction enhancer
US20230071627A1 (en) 2020-02-03 2023-03-09 Amgen Inc. Multivariate Bracketing Approach for Sterile Filter Validation
TW202140561A (zh) 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
EP4110826A4 (en) 2020-02-28 2024-08-14 Shanghai Henlius Biotech Inc ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
WO2021170067A1 (zh) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
IL296601A (en) 2020-03-19 2022-11-01 Amgen Inc Antibodies against mucin 17 and their uses
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20220017636A1 (en) 2020-05-19 2022-01-20 Amgen Inc. Mageb2 binding constructs
TW202210101A (zh) 2020-05-29 2022-03-16 美商安進公司 與ｃｄ３３和ｃｄ３結合的雙特異性構建體的減輕不良反應投與
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
MX2022015376A (es) 2020-06-02 2023-04-14 Dynamicure Biotechnology Llc Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
US20230203198A1 (en) 2020-06-04 2023-06-29 Amgen Inc. Bispecific binding constructs
TW202221029A (zh) 2020-07-29 2022-06-01 美商當康生物科技有限公司 抗cd93之構築體及其用途
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
AU2021331170A1 (en) 2020-08-27 2023-03-23 Juntendo Educational Foundation Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
MX2023002881A (es) 2020-09-11 2023-04-24 Amgen Inc Materiales y metodos para reducir la agregacion de proteinas.
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
WO2022079290A2 (en) 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
CR20230235A (es) 2020-11-06 2023-10-05 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
IL302599A (en) 2020-11-06 2023-07-01 Amgen Inc Bispecific molecules bind multi-target antigens of increased selectivity
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
EP4243936A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
KR20230117397A (ko) 2020-12-03 2023-08-08 암젠 인크 다중 결합 도메인을 갖는 분자
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
IL303740A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides that recruit T cells based on reactivity to alpha/beta receptors
WO2022159984A1 (en) 2021-01-22 2022-07-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
MX2023009244A (es) 2021-02-09 2023-09-11 Us Health Anticuerpos contra la proteina espicular de coronavirus.
WO2022173689A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CN114452403A (zh) 2021-02-10 2022-05-10 同润生物医药(上海)有限公司 一种含有双功能免疫检查点/TGFβ抑制剂的药物组合
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
CN117043173A (zh) 2021-03-10 2023-11-10 美国安进公司 重组蛋白的纯化方法
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
EP4304755A1 (en) 2021-03-10 2024-01-17 Amgen Inc. Parallel chromatography systems and methods
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用
MX2023012931A (es) 2021-05-06 2023-11-13 Amgen Res Munich Gmbh Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
JP2024535249A (ja) 2021-09-17 2024-09-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
IL311714A (en) 2021-10-15 2024-05-01 Amgen Res Munich Gmbh Subcutaneous administration of antibodies that engage CD19-binding T cells
TW202326113A (zh) 2021-10-27 2023-07-01 美商安進公司 使用光譜學進行的基於深度學習的預測
EP4180035A1 (en) 2021-11-15 2023-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses
KR20240116828A (ko) 2021-12-14 2024-07-30 씨디알-라이프 아게 이중 mhc-표적화 t 세포 관여자
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
AU2023224210A1 (en) 2022-02-23 2024-07-18 Amgen Inc. Cancer treatment targeting dll3
WO2023163087A1 (ja) 2022-02-25 2023-08-31 学校法人順天堂 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
TW202413418A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 抗bcma抗體
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024092033A1 (en) 2022-10-26 2024-05-02 Amgen Inc. Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024138155A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2063035A1 (en) 1991-03-27 1992-09-28 Klaus Karjalainen Chimaeric antibodies containing the ligand domain of cd4
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
CA2218898A1 (en) * 1995-05-17 1996-11-21 Duo Wang Immunoconjugates comprising single-chain variable region fragments of anti-cd19 antibodies
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками

Also Published As

Publication number Publication date
HUP0102535A3 (en) 2005-12-28
CA2326389C (en) 2007-01-23
NZ507381A (en) 2003-12-19
CN1302103C (zh) 2007-02-28
NO20005296L (no) 2000-12-13
CZ302070B6 (cs) 2010-09-29
HRP20000714A2 (en) 2001-12-31
HUP0102535A2 (hu) 2001-10-28
PL344016A1 (en) 2001-09-24
WO1999054440A1 (en) 1999-10-28
AU761587B2 (en) 2003-06-05
IL138857A0 (en) 2001-10-31
DE69909459D1 (de) 2003-08-14
ID27512A (id) 2001-04-12
JP2002512020A (ja) 2002-04-23
KR100508289B1 (ko) 2005-08-17
SK286683B6 (sk) 2009-03-05
KR20010071150A (ko) 2001-07-28
US7575923B2 (en) 2009-08-18
CN1299410A (zh) 2001-06-13
JP4169478B2 (ja) 2008-10-22
ZA200005866B (en) 2001-04-18
HRP20000714B1 (en) 2006-03-31
CZ20003889A3 (cs) 2001-03-14
EP1071752A1 (en) 2001-01-31
DE69909459T2 (de) 2004-05-27
US20060193852A1 (en) 2006-08-31
BRPI9909860B8 (pt) 2021-05-25
CA2326389A1 (en) 1999-10-28
IL138857A (en) 2007-08-19
BR9909860A (pt) 2000-12-19
PL199747B1 (pl) 2008-10-31
HU229039B1 (en) 2013-07-29
RU2228202C2 (ru) 2004-05-10
EP1348715A3 (en) 2003-11-19
CU23252B7 (es) 2007-12-17
SK15792000A3 (sk) 2001-05-10
ES2203141T3 (es) 2004-04-01
AU4135299A (en) 1999-11-08
BRPI9909860B1 (pt) 2016-05-31
EP1348715A2 (en) 2003-10-01
NO20005296D0 (no) 2000-10-20
ATE244758T1 (de) 2003-07-15
NO326523B1 (no) 2008-12-22
US7112324B1 (en) 2006-09-26
SI1071752T1 (en) 2003-12-31
TR200003087T2 (tr) 2001-02-21
EP1071752B1 (en) 2003-07-09
PT1071752E (pt) 2003-11-28
HK1037674A1 (en) 2002-02-15

Similar Documents

Publication Publication Date Title
DK1071752T3 (da) CD19xCD3-specifikke polypeptider og anvendelsen deraf
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
CA2072249A1 (en) Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
UA27763C2 (uk) Рекомбінантна молекула днк, що кодує молекулу адгезії icam-3, молекула адгезії icam-3, антитіло, здатне зв'язуватись з такою молекулою, фармацевтична композиція
EP0724456A4 (en) ANTIBODIES AGAINST CD40
EP0739350A4 (en) LIGAND FIXING FAS ANTIGEN
AU7272491A (en) Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
ATE296312T1 (de) Metalkomplexbildner
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
EE05293B1 (et) RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine
BG104868A (en) CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
WO1999029720A3 (en) Mammalian alpha helical protein-1
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
WO2004039952A8 (en) Methods of use for novel human polypeptides encoded by polynucleotides
WO2002046417A3 (en) Adipocyte complement related protein zacrp3x2
IL94304A0 (en) Novel tumor-associated antigen,antibodies,compositions and uses therefor
AU5990100A (en) ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
WO2002020567A3 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
WO2002050274A3 (en) Seleno-cysteine containing protein zsel1
GR890100333A (en) Antihuman antigen antibodies